ERBB2 and breast carcinoma: This study developed a ViT‐based deep learning model using DCE‐MRI to non‐invasively assess HER2 expression in breast cancer, identifying HER2‐low/positive cases and further distinguishing between HER2‐low and HER2‐positive subtypes.